ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$0.45 USD
-0.02 (-4.68%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $0.45 0.00 (0.45%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.45 USD
-0.02 (-4.68%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $0.45 0.00 (0.45%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Zacks News
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
by Zacks Equity Research
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
by Zacks Equity Research
ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now
by Zacks Equity Research
Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.
ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study
by Zacks Equity Research
ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price of the company fell by 25%.
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
by Zacks Equity Research
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Atreca, Inc. (BCEL) have performed compared to their sector so far this year.
Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Apexigen, Inc. (APGN) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.
Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now
by Zacks Equity Research
ASLAN Pharmaceuticals Ltd. (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Aspira (AWH) have performed compared to their sector so far this year.
DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study
by Zacks Equity Research
The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
by Zacks Equity Research
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study
by Zacks Equity Research
ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.
Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
by Zacks Equity Research
The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.
Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe
by Zacks Equity Research
Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the European Medicines Agency.
Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth
by Zacks Equity Research
Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie
by Zacks Equity Research
AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.
Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474
by Zacks Equity Research
Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.
Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis
by Zacks Equity Research
The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab
by Zacks Equity Research
Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.
BEAM Up as FDA Lifts Clinical Hold on the IND for BEAM-201
by Zacks Equity Research
The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. Stock up.
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study
by Zacks Equity Research
Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.
Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
by Zacks Equity Research
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics
by Zacks Equity Research
BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs targeting immune modulation in cancer and other diseases. Stock up.